Endocyte to Present Data on EC145 at the IASLC 13th World Conference on Lung Cancer

WEST LAFAYETTE, Ind.--(Business Wire)--
Endocyte Inc., a cancer drug discovery and development company, today announced
that it would report results of a Phase II clinical study of EC145 in patients
with advanced lung cancer. The data will be presented as part of the 13th World
Conference on Lung Cancer to be held July 31 to August 4, 2009, in San
Francisco.

Dr. Martin Edelman, of the Greenebaum Cancer Center, University of Maryland,
principle investigator of the study, will present the data during a session
entitled "Catch and Release: Intracellularly Activated Chemotherapy" on
Saturday, August 1 from 2:00 - 4:30 p.m. in the Moscone Center West, Rooms
3020-3022, Level 3, PD 3.4.4.

About Endocyte

Endocyte is a privately-held biotechnology company with headquarters in the
Purdue Research Park of West Lafayette, IN. Based on the applications of
Endocyte`s advanced proprietary Drug Guidance System (DGS), the company is
working to develop new drugs and diagnostic agents to treat many types of cancer
and other serious diseases. The DGS platform makes it possible to use
highly-potent drugs on extended and frequent dosing schedules and in combination
with other drugs to maximize efficacy. The technology improves drug targeting
and reduces the risk of side effects by combining drugs with ligands that are
able to identify and attach to receptors found on tumor and other disease cells.
Endocyte`s clinical development of EC20 and EC145 is progressing with the recent
completion of accrual for the phase II trials in advanced ovarian and lung
cancer. EC20 and EC145 are now being studied in an international randomized
phase II trial of EC145 in combination with Doxil for the treatment of women
with platinum resistant ovarian cancer. Other clinical-stage products in the
Endocyte pipeline include: EC0225, a targeted combination of two potent
anticancer drugs; BMS753493, a potent drug being developed in partnership with
Bristol-Myers Squibb; EC0489, a targeted cancer drug and EC17, a targeted
immunotherapy agent. The company also has multiple product candidates in
pre-clinical stage of development.

Endocyte Inc.
Vickey Buskirk, media relations, 765-463-7175 ext. 1117
vbuskirk@endocyte.com
or
Purdue Research Foundation
Cynthia Sequin, 765-588-3340
casequin@prf.org

Copyright Business Wire 2009